9 Meters Biopharma, Inc.
NMTRQ
$0.00
$0.000.00%
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.25% | -8.02% | 1.30% | 43.03% | 35.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.52% | 17.20% | 3.32% | 35.56% | 110.48% |
| Operating Income | -12.52% | -17.20% | -3.32% | -35.56% | -110.48% |
| Income Before Tax | -22.17% | -24.86% | 30.91% | -34.86% | -109.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.17% | -24.86% | 30.91% | -34.86% | -109.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.17% | -24.86% | 30.91% | -34.86% | -109.01% |
| EBIT | -12.52% | -17.20% | -3.32% | -35.56% | -110.48% |
| EBITDA | -12.53% | -17.21% | -3.32% | -35.57% | -110.50% |
| EPS Basic | -16.05% | -23.31% | 32.20% | -29.95% | -71.02% |
| Normalized Basic EPS | -12.59% | -28.46% | -8.83% | -29.95% | -71.02% |
| EPS Diluted | -15.94% | -22.95% | 32.20% | -29.95% | -71.17% |
| Normalized Diluted EPS | -12.59% | -28.46% | -8.83% | -29.95% | -71.02% |
| Average Basic Shares Outstanding | 5.27% | 1.26% | 1.90% | 3.79% | 22.22% |
| Average Diluted Shares Outstanding | 5.27% | 1.26% | 1.90% | 3.79% | 22.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
